{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nirsevimab",
    "query": {
      "intervention": "Nirsevimab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T03:20:03.324Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06172660",
      "title": "Real-World Effectiveness of Perinatal RSV Immunoprophylaxis",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "RSV Infection"
      ],
      "interventions": [
        {
          "name": "Nirsevimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "Up to 12 Months"
      },
      "enrollment_count": 3750,
      "start_date": "2024-10-28",
      "completion_date": "2028-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-09-04T03:20:03.324Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06172660"
    },
    {
      "nct_id": "NCT06325332",
      "title": "BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Respiratory Syncytial Virus"
      ],
      "interventions": [
        {
          "name": "Nirsevimab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Days",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "0 Days to 12 Months"
      },
      "enrollment_count": 49680,
      "start_date": "2024-04-01",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-09-04T03:20:03.324Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06325332"
    },
    {
      "nct_id": "NCT06551506",
      "title": "The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infection"
      ],
      "interventions": [
        {
          "name": "Abrysvo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Beyfortus",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 181,
      "start_date": "2024-09-19",
      "completion_date": "2026-05-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-09-04T03:20:03.324Z",
      "location_count": 8,
      "location_summary": "Atlanta, Georgia • Baltimore, Maryland • New York, New York + 5 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06551506"
    },
    {
      "nct_id": "NCT05743881",
      "title": "A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus",
        "Human Metapneumovirus"
      ],
      "interventions": [
        {
          "name": "mRNA-1345",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1365",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nimenrix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Months",
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "5 Months to 24 Months"
      },
      "enrollment_count": 186,
      "start_date": "2023-02-15",
      "completion_date": "2029-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-09-04T03:20:03.324Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Melrose Park",
          "state": "Illinois"
        },
        {
          "city": "Lafayette",
          "state": "Louisiana"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05743881"
    },
    {
      "nct_id": "NCT07158814",
      "title": "Safety of RSV Preventive Monoclonal Antibody",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fever",
        "Adverse Event Following Immunisation"
      ],
      "interventions": [
        {
          "name": "Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "30 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 30 Weeks"
      },
      "enrollment_count": 524,
      "start_date": "2025-10-02",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-09-04T03:20:03.324Z",
      "location_count": 6,
      "location_summary": "Oakland, California • Atlanta, Georgia • New York, New York + 2 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07158814"
    },
    {
      "nct_id": "NCT04484935",
      "title": "Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "RSV Infection"
      ],
      "interventions": [
        {
          "name": "Nirsevimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "2 Years",
        "sex": "ALL",
        "summary": "0 Years to 2 Years"
      },
      "enrollment_count": 100,
      "start_date": "2020-08-19",
      "completion_date": "2023-02-17",
      "has_results": true,
      "last_update_posted_date": "2023-11-15",
      "last_synced_at": "2026-09-04T03:20:03.324Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Tampa, Florida • Syracuse, New York + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "North Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04484935"
    }
  ]
}